---
title: "Relmada Therapeutics, Inc. (RLMD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RLMD.US.md"
symbol: "RLMD.US"
name: "Relmada Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-04-15T22:54:41.389Z"
locales:
  - [en](https://longbridge.com/en/quote/RLMD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RLMD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RLMD.US.md)
---

# Relmada Therapeutics, Inc. (RLMD.US)

## Company Overview

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.relmada.com](https://www.relmada.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -13.14 | 197 | - | - | - |
| PB | 8.72 | 175 | 32.07 | 4.43 | 0.93 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-24T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 80% |
| Overweight | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.18 |
| Highest Target | 19.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RLMD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RLMD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RLMD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RLMD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**